# A Phase 1 Trial of ABI-011 in Patients With Advanced Solid Tumors or Lymphomas

> **NCT01163071** · PHASE1 · TERMINATED · sponsor: **Celgene** · enrollment: 60 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** ABI-011

## Key facts

- **NCT ID:** NCT01163071
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-03-01
- **Primary completion:** 2011-09-23
- **Final completion:** 2011-09-23
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2019-11-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01163071

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01163071, "A Phase 1 Trial of ABI-011 in Patients With Advanced Solid Tumors or Lymphomas". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01163071. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*